WallStSmart

Envoy Medical Inc. (COCH)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 2400480% more annual revenue ($4.97B vs $207,000). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).

COCH

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 3.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -60.53

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

COCHUndervalued (+40.6%)

Margin of Safety

+40.6%

Fair Value

$1.11

Current Price

$0.73

$0.38 discount

UndervaluedFair: $1.11Overvalued

Intrinsic value data unavailable for DXCM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COCH1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

Areas to Watch

COCH4 concerns · Avg: 3.5/10
Price/BookValuation
14.6x4/10

Trading at 14.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$57.14M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : COCH

The strongest argument for COCH centers on Debt/Equity.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : COCH

The primary concerns for COCH are Price/Book, EPS Growth, Market Cap.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

COCH profiles as a value stock while DXCM is a mature play — different risk/reward profiles.

COCH carries more volatility with a beta of 1.90 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (74/100 vs 15/100), backed by strong 20.1% margins and 13.1% revenue growth. COCH offers better value entry with a 40.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Envoy Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Envoy Medical Corporation manufactures and markets an implantable hearing aid device. The company is headquartered in White Bear Lake, Minnesota.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?